Does successful control of high intra‑ocular pressure with Combigan (brimonidine 0.2%/timolol 0.5%) indicate a lower risk of developing aggressive glaucoma?

Successful IOP Control with Combigan Does NOT Predict Lower Risk of Aggressive Glaucoma

Controlled intraocular pressure with Combigan (or any medication) does not predict whether glaucoma will be aggressive—it only modifies one risk factor (IOP) while multiple other independent risk factors determine disease progression. The concept of "aggressive glaucoma" relates to the rate and severity of progression, which depends on both IOP-dependent and IOP-independent factors that persist regardless of pressure control 1.

Understanding the Relationship Between IOP Control and Glaucoma Risk

IOP Control Reduces But Does Not Eliminate Risk

The evidence is clear that lowering IOP reduces the risk of conversion from ocular hypertension to glaucoma and slows progression in established disease. In the Ocular Hypertension Treatment Study (OHTS), IOP reduction decreased the risk of developing POAG from 9.5% to 4.5% over 5 years 1. However, this still means that even with treatment, progression can occur—the risk is reduced, not eliminated.

Combigan (brimonidine 0.2%/timolol 0.5%) is FDA-approved for reducing elevated IOP in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy 2. It works through dual mechanisms: brimonidine reduces aqueous production and increases uveoscleral outflow, while timolol decreases aqueous production 2. Studies demonstrate that fixed-combination brimonidine/timolol provides superior IOP control compared to either component as monotherapy 3, 4.

IOP-Independent Risk Factors Persist Despite Pressure Control

Critical point: Multiple risk factors for glaucoma progression operate independently of IOP level 5. These include:

• Older age - consistently associated with higher progression risk
• Disc hemorrhages - strongly predictive of progression in both normal-tension and high-pressure glaucoma
• Larger cup-to-disc ratio or smaller rim area
• Beta-zone parapapillary atrophy
• Thinner central corneal thickness (though evidence is mixed for progression in established glaucoma)
• Decreased corneal hysteresis
• Lower ocular perfusion pressure
• Pseudoexfoliation
• Poor medication adherence

These factors continue to influence disease behavior regardless of whether target IOP is achieved 5.

The Baseline Risk Profile Matters More Than Response to Treatment

The OHTS data illustrate this principle clearly: untreated patients with baseline IOP ≥26 mmHg and central corneal thickness (CCT) ≤555 μm had a 36% chance of developing optic nerve damage during follow-up, compared to only 2% risk for patients with baseline IOP <24 mmHg and CCT >588 μm 1. The baseline risk stratification—not the response to medication—determines the likelihood of aggressive disease.

Risk calculators incorporating age, vertical cup-to-disc ratio, pattern standard deviation, CCT, and IOP can estimate 5-year risk of progression from ocular hypertension to POAG 1. These tools (available at https://ohts.wustl.edu/risk/) demonstrate that multiple factors beyond IOP control determine overall risk.

Target IOP is an Estimate, Not a Guarantee

When treating glaucoma suspects, a reasonable target IOP based on OHTS would be 20% lower than baseline measurements 1. However, achieving target pressure does not guarantee stability—it represents an estimated upper limit at which visual field loss is unlikely to significantly affect quality of life over the patient's lifetime 1.

Definite deterioration in optic nerve structure or visual field despite achieving target IOP indicates the target was insufficient, and the patient should be managed as having converted to POAG with a lower target pressure 1.

Monitoring Remains Essential Regardless of IOP Control

Whether or not a patient is treated and regardless of IOP response, long-term monitoring for development or progression of glaucoma is essential 1, 6, 1. This includes:

• Monitoring for structural changes in the optic disc and retina (RNFL and/or macular analysis)
• Monitoring for functional changes via visual field assessment
• Periodic fundus imaging with disc photography and computerized imaging 1

The goals of management focus on monitoring or lowering IOP if an eye is likely to progress to POAG, not assuming that controlled IOP eliminates risk 1.

Special Considerations with Brimonidine

Brimonidine may offer potential neuroprotective effects independent of IOP lowering 7, 8. The Low-Pressure Glaucoma Treatment Study found that significantly fewer brimonidine-treated patients (9.1%) had visual field progression compared to timolol-treated patients (39.2%), despite similar IOP control 7. However, 28.3% of brimonidine patients discontinued due to adverse events (primarily ocular allergy) versus 11.4% with timolol 7.

This suggests that medication choice may influence outcomes beyond IOP reduction alone, but does not change the fundamental principle that controlled IOP does not predict absence of aggressive disease.

Clinical Algorithm for Risk Assessment

When evaluating a patient with controlled IOP on Combigan:

1. Assess baseline risk factors (age, family history, race/ethnicity, CCT, disc appearance, baseline IOP)
2. Use risk calculators to quantify 5-year progression risk 1
3. Monitor for IOP-independent risk factors (disc hemorrhages, parapapillary atrophy, perfusion pressure)
4. Continue regular structural and functional monitoring regardless of IOP control
5. Recognize that achieving target IOP is necessary but not sufficient to prevent progression
6. Lower target IOP if any progression occurs despite apparent control 1

Common Pitfalls to Avoid

• Do not assume IOP control equals disease control - progression can occur at any IOP level
• Do not extend monitoring intervals excessively based solely on good IOP response
• Do not ignore structural changes (disc hemorrhages, RNFL thinning) when IOP is at target
• Do not overlook medication adherence issues - poor adherence is itself a risk factor for progression 5
• Do not forget that brimonidine causes allergic reactions in a substantial minority (28% discontinuation rate in some studies) 7

The bottom line: Successful IOP control with Combigan modifies one important risk factor but does not predict the absence of aggressive glaucoma behavior, as multiple IOP-independent factors continue to influence disease progression.